Efficace Fabio, Vignetti Marco, Sparano Francesco, Scalzulli Emilia, Breccia Massimo
Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Department of Cellular Biotechnologies and Hematology, "Sapienza" University of Rome, Rome, Italy.
Expert Rev Hematol. 2021 Mar;14(3):293-302. doi: 10.1080/17474086.2021.1886918. Epub 2021 Mar 9.
: The current treatment landscape of chronic myeloid leukemia (CML) is challenging for several reasons, and health-related quality of life (HRQOL) data may be of critical importance to help physicians and patients make more informed decisions.: A systematic literature search was performed in PubMed to identify the most recent studies (between April 2016 and June 2020) assessing the impact of tyrosine kinase inhibitors (TKIs) on adult CML patients' HRQOL. Studies assessing treatment discontinuation were also considered. For each study, we evaluated characteristics of CML patients included, treatment information and basic HRQOL data, including questionnaires used, and summary findings.: Valuable information can be gleaned from recent CML studies including a HRQOL assessment; however, major gaps remain in our knowledge. These include, for example, a better understanding of the impact of second- and third-generation TKIs on patients' HRQOL compared to imatinib therapy. Also, the benefits of TKI treatment discontinuation, in terms of symptom burden and HRQOL, are yet to be fully elucidated. More research efforts are needed in this area to generate high-quality evidence that can facilitate decision-making.
慢性髓性白血病（CML）当前的治疗格局面临诸多挑战，原因有多种，而健康相关生活质量（HRQOL）数据对于帮助医生和患者做出更明智的决策可能至关重要。在PubMed中进行了系统的文献检索，以确定评估酪氨酸激酶抑制剂（TKIs）对成年CML患者HRQOL影响的最新研究（2016年4月至2020年6月期间）。还考虑了评估治疗中断情况的研究。对于每项研究，我们评估了纳入的CML患者的特征、治疗信息和基本HRQOL数据，包括所使用的问卷以及总结结果。可以从近期包括HRQOL评估的CML研究中收集到有价值的信息；然而，我们的认知中仍存在重大差距。例如，与伊马替尼治疗相比，对第二代和第三代TKIs对患者HRQOL的影响还需要更好地理解。此外，就症状负担和HRQOL而言，TKI治疗中断的益处尚未完全阐明。该领域需要更多的研究努力来生成高质量的证据，以促进决策制定。
